Does Priority Health Cover Prolia?

What Prolia Is and Why Coverage Decisions Are Complex

Prolia is a RANK ligand (RANKL) inhibitor that reduces osteoclast activity and slows bone resorption. The FDA approved denosumab 60 mg in May 2010 for postmenopausal women with osteoporosis at high fracture risk, and later for men with osteoporosis, glucocorticoid-induced osteoporosis, and bone loss associated with hormone ablation therapy in prostate or breast cancer. [1]

Coverage decisions are complex because Prolia is a biologic injectable. Insurers classify it differently from oral generic bisphosphonates, which cost as little as $4 per month. That cost gap drives formulary management practices including prior authorization, step therapy, and quantity limits.

Why Priority Health Uses Prior Authorization for Prolia

Priority Health, a Michigan-based health plan, applies prior authorization (PA) to most specialty biologics. Prolia's annual cost to a plan can exceed $3,000 per member, which places it squarely in the specialty tier requiring medical justification before dispensing. [2]

PA criteria typically require the prescriber to confirm:

• A diagnosis of osteoporosis, defined by DXA T-score of -2.5 or lower at the spine, hip, or femoral neck, or a qualifying fragility fracture [3]
• Previous trial and failure of, or contraindication to, an oral bisphosphonate such as alendronate or risedronate
• Absence of hypocalcemia at the time of initiation
• Member's age and sex consistent with the approved indication

The Role of RANK Ligand Biology in Formulary Decisions

Because Prolia targets RANKL rather than the hydroxyapatite surface like bisphosphonates, it works through a distinct mechanism. That mechanistic distinction is clinically meaningful for patients who cannot tolerate oral bisphosphonates due to esophageal disease, renal impairment (eGFR <35 mL/min/1.73m²), or documented GI intolerance. [4] Citing this distinction in a PA request can strengthen the case for medical necessity when step therapy requirements conflict with a patient's comorbidities.

Priority Health Formulary Placement for Denosumab

Most Priority Health commercial plans list Prolia on Tier 4 or Tier 5 (specialty biologics). Medicare Advantage plans administered by Priority Health follow CMS formulary guidelines and typically place Prolia under Part B (administered in a physician office or infusion center) rather than Part D, because it is a provider-administered injectable. [5]

Part B vs. Part D: A Critical Distinction

This classification has large financial consequences. Under Part B, the member pays 20% of the Medicare-approved amount after the Part B deductible, with no out-of-pocket cap unless the plan has added supplemental coverage. Under Part D, the IRA-mandated $2,000 annual out-of-pocket cap effective 2025 applies. Confirming how Priority Health classifies Prolia on a specific plan year's Evidence of Coverage document is the first step any patient should take. [6]

Commercial Plan Tiers

On commercial Priority Health plans, Prolia typically appears on the specialty tier with a coinsurance of 20 to 40% rather than a flat copay. A single injection at $1,450 AWP with 30% coinsurance produces a $435 member cost per injection, or $870 per year before deductible. Plans that apply the deductible first push that number higher.

Prior Authorization Criteria in Detail

Standard Medical Necessity Documentation

A PA request for Prolia under Priority Health generally requires: [7]

1. A signed Letter of Medical Necessity from the treating physician
2. DXA scan results with T-scores (scan dated within 24 months)
3. Documentation of bisphosphonate trial (drug name, dose, duration, reason for discontinuation)
4. Current calcium and vitamin D supplementation status
5. Serum calcium level confirming the absence of hypocalcemia
6. Fracture history with imaging reports if applicable

The AACE/ACE 2020 Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis state: "Patients at very high fracture risk, including those with recent fracture, T-score <-3.0, or fractures while on osteoporosis therapy, may be candidates for anabolic or more potent antiresorptive therapy without prior bisphosphonate trial." [8] Quoting this language directly in the PA letter can bypass step therapy requirements for high-risk patients.

Step Therapy Exceptions

Michigan's Step Therapy Reform law, effective 2018 and strengthened in subsequent legislative sessions, requires health insurers to grant a step therapy override when: [9]

• The required first-line drug is contraindicated or expected to cause adverse effects
• The patient already tried and failed the required drug
• The patient is stable on Prolia following a recent transition from another plan
• The required drug is not clinically appropriate based on medical or clinical history

Documenting any of these conditions formally in the PA submission prevents unnecessary delays.

Timeline and Process

Priority Health is required to respond to standard PA requests within 3 to 5 business days under Michigan law for non-urgent cases, and within 1 business day for expedited or urgent requests. [10] Specialty pharmacy prior authorizations may take up to 15 business days if additional clinical records are requested. Setting an internal reminder at day 3 to follow up with the Priority Health pharmacy department avoids silent denials.

What to Do If Priority Health Denies Prolia Coverage

Denial rates for specialty biologics on first submission run 20 to 35% across commercial plans nationally. A denial is not a final answer.

Level 1 Internal Appeal

Submit a Level 1 internal appeal within 180 days of the denial notice. The appeal packet should include: [11]

• The original denial letter
• An updated Letter of Medical Necessity with specific reference to the denied criteria
• FREEDOM trial data (see below)
• AACE guideline quotes supporting use without prior bisphosphonate trial for very high-risk patients
• Any imaging showing vertebral or hip fracture
• Adverse event documentation from prior bisphosphonate use

Key Clinical Evidence to Include in Appeals

The FREEDOM trial (N=7,868) is the cornerstone study for Prolia coverage appeals. At 36 months, denosumab 60 mg every 6 months reduced new vertebral fractures by 68% (RR 0.32; 95% CI 0.26 to 0.41; P<0.001), hip fractures by 40% (HR 0.60; 95% CI 0.37 to 0.97; P=0.04), and nonvertebral fractures by 20% compared with placebo. [12]

The FREEDOM Extension study followed participants for an additional 7 years (10 years total). Bone mineral density continued to increase, and fracture rates remained low. Women transitioned from placebo to denosumab during the extension period achieved fracture reduction comparable to those on continuous therapy. [13]

Level 2 External Appeal and Independent Review

If the Level 1 appeal fails, request an external independent review. Michigan law requires Priority Health to comply with an independent review organization's decision. The review organization receives the full clinical file and must render a decision within 30 to 45 days for standard cases. [14]

During the external review, a board-certified endocrinologist or rheumatologist review note specifically supporting Prolia over bisphosphonates for the patient's clinical profile significantly improves outcomes.

Biosimilar Denosumab: Jubbonti and Wyost

The FDA approved two denosumab biosimilars in 2024: Jubbonti (denosumab-bbdz, Sandoz) at the 60 mg/mL concentration for osteoporosis indications, and Wyost at the 120 mg/1.7 mL concentration for oncology bone loss indications. [15]

What Biosimilar Approval Means for Priority Health Members

Priority Health may substitute Jubbonti for Prolia on its formulary, as the FDA designates it interchangeable. Members should verify with Priority Health whether a biosimilar substitution affects their PA status, copay tier, or any ongoing step therapy requirements. Biosimilars typically carry 15 to 35% lower list prices than the reference biologic, which may reduce specialty tier coinsurance amounts. [16]

Some members already approved for Prolia worry about automatic substitution. Physicians can write "Dispense as Written" (DAW-1) on the prescription to prevent automatic pharmacist substitution, though plan cost-sharing rules may penalize DAW prescriptions by applying a higher member cost.

Cost Reduction Strategies for Priority Health Members

Amgen SupportPlus and the Prolia Co-pay Card

Amgen offers a co-pay assistance program called Amgen SupportPlus for commercially insured patients. Eligible members pay as little as $0 per injection, with a benefit cap that varies by plan year. This program does not apply to government-funded plans including Medicare Advantage or Medicaid. [17]

Patient Assistance Programs

Uninsured or underinsured patients with household income at or below 500% of the federal poverty level may qualify for free Prolia through the Amgen Safety Net Foundation. Applications require proof of income, a prescriber signature, and documentation of insurance denial. Turnaround time runs 2 to 4 weeks for first-time applicants.

Hospital Outpatient vs. Physician Office Administration

Prolia is administered in a clinical setting. The site of service affects Medicare Part B reimbursement rates significantly. Hospital outpatient departments typically bill at higher facility rates than physician office rates, increasing member coinsurance. Patients with Medicare Advantage through Priority Health should confirm whether their prescriber can administer the injection in a physician office (Place of Service 11) to minimize out-of-pocket cost. [18]

Clinical Indications That Support Priority Health Approval

Postmenopausal Osteoporosis at High Fracture Risk

The strongest PA approval pathway follows the FREEDOM trial indication: postmenopausal women aged 60 to 90 years with T-score <-2.5 at the spine or hip, or a prior fragility fracture. The National Osteoporosis Foundation (NOF) FRAX-based threshold for initiating pharmacotherapy in the United States is a 10-year hip fracture probability >3% or a major osteoporotic fracture probability >20%. [19] Including the patient's FRAX score in the PA submission provides quantitative risk context that most PA reviewers accept as objective medical necessity documentation.

Glucocorticoid-Induced Osteoporosis

The FDA approved Prolia for men and women at high fracture risk receiving glucocorticoid therapy equivalent to prednisone 7.5 mg per day or greater for at least 6 months. [20] The ACR 2022 Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis conditionally recommends denosumab for patients at very high fracture risk who cannot use oral bisphosphonates. Citing the ACR guideline by name and page reference in the PA letter carries weight with clinical reviewers.

Male Osteoporosis and Androgen Deprivation Therapy

Men receiving androgen deprivation therapy (ADT) for prostate cancer lose bone mineral density at rates 2 to 8 times faster than age-matched controls. The HALT trial (N=1,468) showed denosumab 60 mg every 6 months increased lumbar spine BMD by 5.7% versus -1.0% with placebo at 24 months (P<0.001). [21] Priority Health medical policy language for male osteoporosis and ADT-related bone loss frequently mirrors these HALT trial criteria.

How to Submit a Prior Authorization to Priority Health: Step-by-Step

The following framework is the HealthRX standard operating procedure developed from PA submissions across multiple Michigan-based Priority Health plan types.

Step 1. Confirm the indication and ICD-10 code. The most common codes for Prolia PA are M81.0 (age-related osteoporosis without current pathological fracture), M80.08XA (age-related osteoporosis with current pathological fracture, vertebra), and Z79.52 (long-term current use of systemic steroids). Using the most specific code available reduces auto-denial rates.

Step 2. Obtain a current DXA report. DXA scans older than 24 months may require re-imaging before PA submission. The International Society for Clinical Densitometry (ISCD) recommends repeat DXA at 1 to 2 year intervals when initiating or changing osteoporosis therapy. [22]

Step 3. Document the bisphosphonate trial. List the drug (alendronate 70 mg weekly, risedronate 35 mg weekly, ibandronate 150 mg monthly, or zoledronic acid 5 mg IV annually), the duration of use, and the specific reason for discontinuation. GI intolerance, esophageal stricture, inability to remain upright for 30 minutes, and eGFR <35 mL/min/1.73m² are all recognized contraindications in Priority Health policy language.

Step 4. Complete Priority Health's PA request form. Priority Health uses a centralized portal at provider.priorityhealth.com. The form for specialty pharmaceuticals requires the NPI of the administering provider, the specialty pharmacy (if applicable), and the anticipated injection date.

Step 5. Submit and track. Log the submission date and PA reference number. Follow up at day 3 if no acknowledgment is received. Request an expedited review if the patient has a recent fracture (within 6 weeks) or is transitioning from another plan.

Monitoring and Reauthorization After Initial Approval

Priority Health typically authorizes Prolia for 12 months (two injections). Reauthorization at 12 months requires documentation that:

• The patient received both scheduled injections without significant adverse events
• Serum calcium remains within normal limits
• There is no evidence of osteonecrosis of the jaw (ONJ) or atypical femoral fracture
• Continued treatment is consistent with long-term fracture risk reduction goals

The FDA label for Prolia notes that discontinuation without transitioning to another antiresorptive agent is associated with multiple vertebral fractures occurring as early as 7 months after the last dose. [23] This rebound fracture risk, documented in a 2017 report in Osteoporosis International (N=24 patients, all postmenopausal women, median time to fracture 9 months after last injection), makes smooth reauthorization medically necessary rather than discretionary.

Prescribers should initiate the reauthorization PA at least 60 days before the patient's next scheduled injection date to avoid a gap in therapy.

Special Populations and Coverage Nuances

Premenopausal Women

Prolia is not FDA-approved for premenopausal osteoporosis as a general indication. Priority Health will almost certainly deny a PA for a premenopausal woman without a specific approved indication such as glucocorticoid-induced osteoporosis or cancer-treatment-related bone loss. Off-label use requires a strong clinical rationale and will likely require Level 2 external appeal. [24]

Medicaid and Dual-Eligible Members

Priority Health administers Michigan Medicaid managed care plans. Medicaid coverage for Prolia follows the Michigan Department of Health and Human Services (MDHHS) preferred drug list. Members enrolled in both Medicare and Medicaid (dual-eligible) have Prolia covered under Medicare Part B, with Medicaid potentially covering the 20% coinsurance as a secondary payer.

Members Transitioning Plans Mid-Therapy

Step therapy protections in Michigan law explicitly state that a patient who is stable on a current therapy must not be required to restart step therapy solely because of a plan change. [9] A member switching to Priority Health mid-course on Prolia therapy should submit documentation of current stable use to trigger this continuity-of-care protection.